IL123383A0 - Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors - Google Patents

Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors

Info

Publication number
IL123383A0
IL123383A0 IL12338396A IL12338396A IL123383A0 IL 123383 A0 IL123383 A0 IL 123383A0 IL 12338396 A IL12338396 A IL 12338396A IL 12338396 A IL12338396 A IL 12338396A IL 123383 A0 IL123383 A0 IL 123383A0
Authority
IL
Israel
Prior art keywords
igf
insulin
treatment
growth factor
binding protein
Prior art date
Application number
IL12338396A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL123383A0 publication Critical patent/IL123383A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12338396A 1995-09-14 1996-09-12 Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors IL123383A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US373095P 1995-09-14 1995-09-14
PCT/US1996/014623 WO1997009998A2 (fr) 1995-09-14 1996-09-12 Proteine de liaison 3 du facteur de croissance insulinoide (igf-bp3) dans le traitement de tumeurs liees a p53

Publications (1)

Publication Number Publication Date
IL123383A0 true IL123383A0 (en) 1998-09-24

Family

ID=21707302

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12338396A IL123383A0 (en) 1995-09-14 1996-09-12 Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors

Country Status (8)

Country Link
US (1) US5840673A (fr)
EP (1) EP0871475A2 (fr)
JP (1) JP2000502322A (fr)
AU (1) AU718451B2 (fr)
CA (1) CA2232000A1 (fr)
IL (1) IL123383A0 (fr)
NO (1) NO981127L (fr)
WO (1) WO1997009998A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
WO2000041730A1 (fr) 1999-01-13 2000-07-20 Meditech Research Limited Composition visant a accroitre l'efficacite de medicaments et methodes afferentes
AU3579200A (en) * 1999-02-26 2000-09-14 Saltech I Goteborg Ab Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1
EP1290162A4 (fr) * 2000-05-17 2005-08-17 Univ Oregon Health Sciences Induction de l'apoptose et inhibition de la croissance cellulaire par la proteine 4.33 (p4.33)
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AU2001291090B2 (en) * 2000-09-19 2007-05-10 Bioexpertise, Llc Method for use of IGF-binding protein for selective sensitization of target cells in vivo
US20050042303A1 (en) * 2001-08-27 2005-02-24 Brown Tracey Jean Therapeutic protocols
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
EP1435986B1 (fr) * 2001-09-18 2008-01-02 Bioexpertise, Llc Peptide derive de proteines de liaison de l'igf
WO2003068160A2 (fr) * 2002-02-13 2003-08-21 The Trustees Of Columbia University In The City Of New York Utilisation de la proteine 3 (igf-bp3) de facteur de croissance de type insuline dans le but d'inhiber la croissance d'une tumeur
US20040005294A1 (en) * 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer
WO2004111262A1 (fr) * 2003-06-18 2004-12-23 Pharmacia & Upjohn Company Llc Procede d'identification d'un agent chimiotherapeutique selectif
CA2541015A1 (fr) * 2003-10-03 2005-04-14 Genentech, Inc. Proteines de liaison a l'igf
US20060084603A1 (en) * 2004-08-06 2006-04-20 Irena Kirman IGF-BP3-related methods for inhibiting tumor growth
JPWO2006070577A1 (ja) * 2004-12-28 2008-06-12 独立行政法人海洋研究開発機構 浮沈フロートおよび浮沈フロートの使用方法
EP1912658B1 (fr) * 2005-07-27 2017-01-25 Alchemia Oncology Pty Limited Protocoles thérapeutiques utilisant le hyaluronan
CN101287475B (zh) * 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT661990E (pt) * 1992-08-26 2002-09-30 Celtrix Pharma Metodo para tratamento sistemico de condicoes catabolicas e de lesoes sistemicas em tecidos
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains

Also Published As

Publication number Publication date
JP2000502322A (ja) 2000-02-29
US5840673A (en) 1998-11-24
NO981127D0 (no) 1998-03-13
AU6975296A (en) 1997-04-01
MX9801704A (es) 1998-05-31
WO1997009998A3 (fr) 1997-04-10
WO1997009998A2 (fr) 1997-03-20
AU718451B2 (en) 2000-04-13
EP0871475A2 (fr) 1998-10-21
NO981127L (no) 1998-03-13
CA2232000A1 (fr) 1997-03-20

Similar Documents

Publication Publication Date Title
IL123383A0 (en) Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors
EP0785276A4 (fr) Modification d'un peptide et d'une proteine
HUP9601120A2 (en) Recombinant obese (ob) proteins
AU4230196A (en) Treatment of pancreatic tumors with peptide yy and analogs thereof
ZA969444B (en) Peptides which enhance transport across tissues and methods of identifying and using the same
EP0742793A4 (fr) Proteines associees a la bcl-2
EP1007964A4 (fr) FORMATION ET UTILISATION DE COMPLEXES DE PROTEINES PRIONS (PrP)
ZA964733B (en) Ob protein compositions and methods
AU3118897A (en) Immunoassay of total insulin-like growth factor binding protein-1
AU4514193A (en) Bone formation-inducing protein
AU5716696A (en) Decorin binding protein compositions and methods of use
ZA955430B (en) Tumor necrosis factor receptor-ii associated protein kinase and method for their use
EP0750848A4 (fr) Produit de modification et composition de modification pour substances contenant des proteines
GB2305179B (en) Small cell lung carcinoma peptides and binding agents
AU5446694A (en) Process for enhancing the content of a selected amino acid in a seed storage protein
IL114417A0 (en) Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use
AU2186895A (en) Polypeptides of lipopolysaccharide binding protein
AU1888692A (en) Composition and method for treating tumors
EP0546081A4 (en) New insulin-like growth factor binding protein (igfbp-4)
ZA963530B (en) Recombinant obese (ob) proteins
HUP9900011A3 (en) Use of protein gax for treating cancer
AU3942097A (en) Amino acid composition and use thereof in treating tumor growth and metastasis
AU4687997A (en) In vivo protein synthesis method
IL128444A0 (en) Conjugated peptides immunological reagent containing same and use thereof for treatment of immunological disorders
EP0704453A4 (fr) Nouveau complexe de platine (ii) et medicament contre les tumeurs malignes